Enara Bio

The countdown has started to the 3rd Annual Dark Genome Symposium in New York. See below for details of how to submit abstracts on your research! #DarkAntigens #DarkGenome #DarkGenomeSymposium #DGS2024

After tremendous success the last two years, we are delighted to be co-hosting the 3rd Annual Dark Genome Symposium in New York on 20-21 November 2024. The event brings together leaders from academia, industry, and the investment community to discuss future directions in dark genome research and the development of novel therapeutics. See below for details on how to register for the symposium or submit abstracts on your research. We look forward to seeing you there! #DarkAntigens #DarkGenome #DarkGenomeSymposium #DGS2024 

Sunday is World Cancer Day. At Enara Bio, we are proud to be at the cutting edge of the global effort to prevent, treat, and cure cancer. We are committed to our goal of finding novel immunotherapy targets from the Dark Genome and developing innovative treatments that will improve survival outcomes for cancer patients.     To mark World Cancer Day, this week our Sports and Social Team arranged our first charity morning of the year. It was great to take time to raise money for charities that provide tireless support for cancer patients. A great cause that links so closely with the work we do at Enara.  #worldcancerday  #closethecaregap #DarkAntigens #DarkGenome #EnaraBio #Biotech 

At Enara Bio, we are firm believers that collaboration is an essential part of advancing science and developing new treatments for patients. Our partnership with Boehringer Ingelheim has been a key part of our mission to shine a light on the dark genome to discover novel insights into cancer. We are delighted that by licensing multiple Dark Antigens discovered via our EDAPT platform, Boehringer Ingelheim can advance the next generation of cancer vaccines for the treatment of lung cancer. #DarkAntigens #DarkGenome #Collaboration #EnaraBio #Biotech

To recognise Blue Monday and the importance of mental health in the workplace, Enara Bio would like to introduce some of our newly certified Mental Health First Aiders (or MHFAider). We are proud that 8 of our Enarians completed the 2-day course back in December. Together we are looking forward to supporting our colleagues and raising awareness about mental health in the workplace in 2024. Abbey Lamb, Kerrie Buchanan, Anna Williams, Assegid Oumie, Heather Mcintyre, Mengqiu Li, Rayner Queiroz, Tatiana Lobry #bluemonday #mhfaengland #mentalhealth #enarians

We are delighted that Boehringer Ingelheim exercised its first option to license multiple antigens identified by our EDAPT Dark Antigen discovery platform. We are looking forward to continuing this exciting partnership! Full press release: https://lnkd.in/ekGNc6FD

We are thrilled to share a major milestone in our collaboration with Boehringer Ingelheim. Boehringer has exercised its option to license multiple Dark Antigens® from Enara Bio to develop novel off-the-shelf immunotherapies for the treatment of non-small cell lung cancer (NSCLC). During the collaboration, we demonstrated that these antigens have several attractive characteristics as targets for immunotherapies, including high prevalence in NSCLC patients, confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity. In addition, Boehringer Ingelheim has triggered the remaining component of the collaboration to initiate antigen discovery in another solid tumor. Follow the link for our full press release and to learn more about Dark Antigens: https://lnkd.in/ekGNc6FD #DarkAntigens #DarkGenome #Immunotherapy #EnaraBio #Biotech

We are pleased to share that Joe Dukes, our CSO, was guest editor of the December 2023 issue of Immuno-Oncology Insights published by BioInsights. Sophie Papa, our CMO and Head of Translational Science, also contributed an article discussing the optimal selection of tumor antigens for TCR-based immunotherapies. At Enara Bio, we firmly believe that unlocking the full potential of immunotherapy, particularly for solid tumors, rests with the ability to identify novel tumor-specific targets. To achieve this goal, we developed a technology platform called EDAPT to discover a novel class of targets that we call Dark Antigens. These targets are derived from regions of the genome historically thought to be non-coding, known as the genomic dark matter. While usually silenced in healthy cells, altered cellular processes in cancer cells lead to the transcription of Dark Antigen-encoding sequences and presentation of novel polypeptides on the surface of tumor cells. EDAPT is discovering Dark Antigens that have minimal or no expression on healthy cells, homogenous expression within tumors, and high prevalence across multiple solid tumors. We believe this makes Dark Antigens ideal targets for immunotherapies that can improve treatment outcomes for broad populations of cancer patients. Visit our website to learn more about EDAPT and Dark Antigens: https://lnkd.in/eJ4dj9CK

Enara Bio is proud to announce that we have achieved 'Green' status, the highest level of the #MyGreenLabCertification program, run by My Green Lab. Recognized by the United Nations #racetozero campaign as a key measure of progress towards a zero-carbon future, My Green Lab Certification is considered the global standard for best practices in laboratory sustainability. We are delighted to join a community of hundreds of labs that have been My Green Lab certified!

We are pleased to see the publication of "A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics" in Nature Reviews today. This collaborative call to change the regulatory thinking around HLA testing was led by the team at Immatics and brought together expertise from Adaptimmune, Affini-T Therapeutics, BioNTech SE, Bristol Myers Squibb, Enara Bio, Immunocore, Medigene AG, Miltenyi Biotec, TKnife USA, TScan Therapeutics, Zelluna Immunotherapy and academia. “This commentary advocates for an update to regulatory frameworks that currently mandate repeat testing of germline invariant HLA alleles each time a patient is being considered for an HLA-restricted therapy. Robust clinical HLA testing is the corner stone of bone marrow transplantation and as such is fit for purpose to establish a person’s HLA alleles, and for that information to be sufficient for therapy selection. We propose removing the unnecessary burden on patients of repeat testing to bring novel T cell receptor based therapies, with real potential of benefit to patients, to the clinic safely and efficiently”, Sophie Papa, CMO and Head of Translational Science at Enara Bio.